Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.50 |
| ▸ | DPP4 | P27487 | 6/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14079941 | 0.84 | DPP4 (0.44) | DPP4DPP8DPP9ALDH1A1KDM1A | |
| SCHEMBL6601840 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1DPP4ALDH1A1 | |
| SCHEMBL16591613 | 0.80 | DPP4 (0.47) | DPP4DPP8DPP9ALDH1A1MEN1 | |
| SCHEMBL25958552 | 0.79 | DPP4 (0.46) | GNAI3GNAO1GNAI1DPP4DPP8 | |
| SCHEMBL23691707 | 0.77 | DPP4 (0.45) | DPP4DPP8DPP9ALDH1A1MEN1 | |
| SCHEMBL20381496 | 0.77 | DPP4 (0.45) | DPP4DPP8DPP9ALDH1A1MEN1 | |
| SCHEMBL20468805 | 0.77 | DPP4 (0.49) | DPP4DPP8DPP9ALDH1A1MEN1 | |
| SCHEMBL5479056 | 0.77 | DPP4 (0.49) | DPP4DPP8DPP9ALDH1A1MEN1 | |
| SCHEMBL25037126 | 0.77 | DPP4 (0.49) | DPP4DPP8DPP9 | |
| SCHEMBL25719587 | 0.76 | DPP4 (0.44) | DPP4DPP8DPP9ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265121-B2 | Chemical compounds | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050026928-A1 | Chemical compounds | ELI LILLY AND COMPANY | 2005-02-03 | — | — | US | disclosed |
| EP-1409479-A2 | 1-GLYCINYL-4-(1-METHYLPIPERIDIN-4-YL)PIPERAZINES AND -PIPERIDINES AS FACTOR XA ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010160-A2 | 1-GLYCINYL-4 (METHYLPIPERIDIN-4-YL) PIPERAZINES AND -PIPERRIDINES AS FACTOR XA ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026928-A1 | Chemical compounds | F2, F12, F11 | GNAI3 2061/4885GNAO1 1436/4885GNAI1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.